Global study presents first results on the longer-term effects of therapies for the treatment of critically ill patients with COVID-19
The world’s largest trial into the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes has released results from a six-month follow-up study of 4,869 critically ill patients.
Published in The Journal of the American Medical Association (JAMA), the study is part of the ongoing Randomized Embedded Multifactorial Adaptive Platform for Community Acquired Pneumonia (REMAP-CAP) trial, and was led by Dr Lisa Higgins from the ANZIC-RC within the School of Public Health and Preventive Medicine.
The study found that among critically ill patients with COVID-19 randomised to receive one or more therapeutic interventions, treatment with an IL-6 receptor antagonist (tocilizumab or sarilumab) led to a greater than 99.9% probability of improved 6-month mortality, whilst antiplatelet agents had a 95% probability of improving 6-month survival.
Read more on the Monash University media release.
Click here for more news from the School of Public Health and Preventive Medicine